Biogen autoimmune news

The European Patent Office (EPO) revoked Biogen’s European Patent No. EP2137537 covering treatment of multiple sclerosis (MS) with 480 mg Tecfidera dimethyl fumarate. Joel Sendek, CFO of Forward Pharma A/S (NASDAQ:FWP, Copenhagen, Denmark), said Forward was one of several parties that challenged the ‘537 patent in Europe. Sendek said Forward holds a European patent covering the 480 mg dose of dimethyl fumarate, adding that “right now, we have an issued patent in Europe and Biogen doesn’t.” ...